Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MC3R | P41968 | 2/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | MC1R | Q01726 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13790198 | 0.89 | MC4R (0.70) | MC4RLMNAGLATSHRMC3R | |
| SCHEMBL13790254 | 0.89 | MC4R (0.70) | MC4RLMNAGLATSHRMC3R | |
| SCHEMBL4511343 | 0.89 | MC4R (0.70) | MC4RLMNAGLATSHRMC3R | |
| SCHEMBL14355922 | 0.89 | MC4R (0.75) | MC4RMC3RMC5RMC1R | |
| SCHEMBL14356065 | 0.88 | MC4R (0.72) | MC4RMC3RMC5RMC1R | |
| SCHEMBL4514396 | 0.87 | MC4R (0.68) | MC4RLMNAGLATSHRMC3R | |
| SCHEMBL14356091 | 0.86 | MC4R (0.72) | MC4RMC3RMC5RMC1R | |
| SCHEMBL14356090 | 0.86 | MC4R (0.72) | MC4RMC3RMC5RMC1R | |
| SCHEMBL13790200 | 0.86 | MC4R (0.67) | MC4RLMNAGLATSHRMC3R | |
| SCHEMBL4518063 | 0.86 | MC4R (0.69) | MC4RLMNAGLATSHRMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885LMNA 3009/4885GLA 2785/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | MC4R 2/4885LMNA 3009/4885GLA 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.